CCL22 and neoplasm: We excitedly found that the immune/stromal/estimate scores (Figures 5A–C) were significantly higher, while tumor purity (Figure 5D) was significantly lower in the high-CCL22-expression subgroup compared to the low-CCL22-expression subgroup, which suggested that CCL22 was closely related to TME.